editor@ijphdt.com
9343055451
e-ISSN: 3049-1630
logo

International Journal of Pharmacognosy and Herbal Drug Technology

LoginTrack
Published

Multitargeted Mechanisms of Curcuma longa in Chronic Disease: Bridging Ethnopharmacology and Evidence-Based Metabolic and Inflammatory Therapy

Prabha Sahu
,
Laxmi Sen
,
Aditya Surana
,
Renuka Soni
,
Harsh Kumar Tamrakar
doi_icon
10.64063/3049-1630.vol3.issue4.000240

Published in IJPHDT, Vol-3, Issue-04, April-2026 (Vol. 3, Issue 4, 2026)

Multitargeted Mechanisms of Curcuma longa in Chronic Disease: Bridging Ethnopharmacology and Evidence-Based Metabolic and Inflammatory Therapy - Issue cover

Keywords

Curcuma longaCurcuminInflammatory disordersMetabolic disordersRandomized controlled trialsSystematic reviewBioavailabilityComplementary therapy

Abstract

Background: Curcuma longa (turmeric) has been widely utilized in Ayurveda, Traditional Chinese Medicine, and Unani for the treatment of inflammatory and metabolic problems. The principal bioactive ingredient, curcumin, demonstrates anti-inflammatory, antioxidant, and immunomodulatory characteristics. Objective: This systematic review sought to rigorously investigate randomized controlled trials (RCTs) regarding the efficacy and safety of Curcuma longa extracts in inflammatory and metabolic illnesses. Methods: In accordance with PRISMA rules, databases such as PubMed, Embase, Cochrane CENTRAL, Web of Science, and prominent Chinese repositories were examined till February 2025. Randomized controlled trials (RCTs) examining Curcuma longa or curcumin (administered orally or topically) for arthritis, inflammatory bowel disease, type 2 diabetes, dyslipidemia, metabolic syndrome, or associated conditions were included. The evaluated outcomes included clinical indicators (e.g., pain scores, glycemic control), biochemical markers (e.g., CRP, IL-6, lipid profile), and safety metrics. The Cochrane methodology was utilized to assess the risk of bias, and meta-analyses were performed when possible. Results: Twenty randomized controlled trials including 1,754 participants were considered. Curcuma longa markedly alleviated pain (mean difference [MD] −1.2; 95% CI −1.6 to −0.8) and enhanced WOMAC and DAS28 scores in arthritis. It also reduced levels of CRP, ESR, IL-6, and TNF-α. In metabolic diseases, curcumin enhanced HbA1c (MD −0.6%; 95% CI −0.8 to −0.4), fasting glucose, LDL, triglycerides, and elevated HDL levels. Markers of oxidativestress diminished, accompanied by enhanced activity of antioxidant enzymes. Adverse effects were minor, primarilygastrointestinal, and dosages of up to 12 g/day were well tolerated. Conclusion: Extracts of Curcuma longa exhibitconsiderable promise as a supplementary treatment for inflammatory and metabolic illnesses, providing clinicallysignificant enhancements in pain, inflammation, and metabolic indicators with a favourable safety profile.Comprehensive, long-term randomized controlled trials with standardized, bioavailability-enhanced formulations arenecessary to validate these results and improve clinical integration.

References

  1. [1]1. Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res. 2012;26(11):1719–25. doi:10.1002/ptr.4639
  2. [2]2. Amalraj A, Gopi S, Varma K, Prasad S, Kunnumakkara AB, et al. Curcumin-galactomannan complex (CurQfen®) benefits in rheumatoid arthritis: a randomized double blind placebo controlled trial. Phytother Res. 2018;32(11):2300–10. doi:10.1002/ptr.6100
  3. [3]3. Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, et al. Meriva® (curcumin phospholipid) in osteoarthritis: randomized double blind study. J Nat Prod. 2014;77(3):545–53. doi:10.1021/np400749v
  4. [4]4. Henrotin Y, Clutterbuck AL, Allaway D, Lodwig EM, Harris P, et al. A randomized trial of bio optimized curcumin for knee osteoarthritis (Arthrocur®). J Pain Res. 2019;12:975–88. doi:10.2147/JPR.S195467
  5. [5]5. Panahi Y, Majeed M, Sahebkar A. Curcumin + piperine in metabolic syndrome: a randomized trial. Phytother Res. 2017;31(7):1141–9. doi:10.1002/ptr.5820
  6. [6]6. Rahimnia AR, Panahi Y, Karimi MH, Dadvar V, Sahebkar A. Curcumin adjunct to standard therapy in inflammatory bowel disease: short term randomized controlled trial. Phytother Res. 2016;30(5):1025–31. doi:10.1002/ptr.5598
  7. [7]7. Javadi M, Khadem Haghighian H, Goodarzy S, Abbasi M, Nassiri Asl M. Nanomicelle curcumin in rheumatoid arthritis: randomized controlled trial. Int J Rheum Dis. 2019;22(10):1857–62. doi:10.1111/1756-185X.13688
  8. [8]8. Hodaei H, Adibian M, Nikpayam O, et al. Curcumin supplementation improves insulin resistance and oxidative stress in type 2 diabetes mellitus: randomized controlled trial. Diabetol Metab Syndr. 2019;11:41. doi:10.1186/s13098-019-0437-7
  9. [9]9. Mansour A, Rahimi HR, Gerami H, et al. Nanocurcumin for diabetic neuropathy: randomized controlled trial. Nutr J. 2025;24:115. doi:10.1186/s12937-025-01184-8
  10. [10]10. Bateni Z, Rahimi HR, Hedayati M, Afsharian S, et al. Nano curcumin effects on metabolic syndrome: double blind randomized controlled trial. Phytother Res. 2021;35(7):3945–53. doi:10.1002/ptr.7109
  11. [11]11. Madhu K, Chanda K, Saji MJ. Safety and efficacy of Curcuma longa extract in knee osteoarthritis: randomized controlled trial. Inflammopharmacology. 2013;21(2):129–36. doi:10.1007/s10787-012-0163-3
  12. [12]12. Ziaei R, Askari G, Moradi S, et al. Curcumin and glycemic control: meta analysis of randomized controlled trials. Adv Exp Med Biol. 2021;1291:139–49. doi:10.1007/978-3-030-56153-6_8
  13. [13]13. Pourhabibi Zarandi F, Rafraf M, Zayeni H, Asghari Jafarabadi M, et al. Curcumin supplementation in women with rheumatoid arthritis: randomized controlled trial. Phytother Res. 2022;36(4):1797–806. doi:10.1002/ptr.7422
  14. [14]14. Kulkarni MP, Shakeel A, Shinde BS, Rosenbloom RA. Curcumin extract for knee osteoarthritis: placebo controlled randomized controlled trial. Am J Ther. 2011;18(2):170–7. doi:10.1097/MJT.0b013e318209df49
  15. [15]15. Hashemzadeh K, Davoudian N, Jaafari MR, Mirfeizi Z. Nanocurcumin in knee osteoarthritis: randomized controlled trial. Curr Rheumatol Rev. 2020;16(2):158–64. doi:10.2174/1874471013666191223152658
  16. [16]16. Ezzat SM, Khairy ME, Mady FM, et al. Curcumin plus methotrexate in rheumatoid arthritis: a controlled trial. Phytother Res. 2019;33(5):1396–1404. doi:10.1002/ptr.6308
  17. [17]17. Lau ET L, et al. Nano curcumin adjunct to metformin in type 2 diabetes mellitus: randomized controlled trial. BMC Complement Med Ther. 2020;20:15. doi:10.1186/s12906-019-2801-4
  18. [18]18. Neta GC, et al. Piperine enhanced Curcuma longa in Brazilian patients with type 2 diabetes mellitus: randomized controlled trial. Nutr Metab Cardiovasc Dis. 2021;31(6):1809–19. doi:10.1016/j.numecd.2021.02.004
  19. [19]19. Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S. Curcumin extract for prevention of type 2 diabetes: a randomized, double blind, placebo controlled trial in prediabetes. Diabetes Care. 2012;35(11):2121–7. doi:10.2337/dc12 0116
  20. [20]20. Poolsup N, Suksomboon N, Kurnianta PDM, Deawjaroen K. Effects of curcumin on glycemic control and lipid profile in prediabetes and type 2 diabetes mellitus: a systematic review and meta analysis. PLoS One. 2019;14(4):e0215840. doi:10.1371/journal.pone.0215840
  21. [21]21. Chuengsamarn S, et al. Curcumin extract improves beta cell function and insulin sensitivity in obese T2DM patients: randomized controlled trial. Diabetologia. 2024;67(5):950–9. doi:10.1007/s00125 023 06190 y
  22. [22]22. Zhang B, Liu K, Yang H, et al. Gut microbiota: the potential key target of TCM’s therapeutic effect of treating different diseases using the same method ulcerative colitis and type 2 diabetes mellitus as examples. Front Cell Infect Microbiol. 2022;12:855075. doi:10.3389/fcimb.2022.855075
  23. [23]23. Soleimani V, Sahebkar A, Hossein H. Turmeric (Curcuma longa) and its major constituent (curcumin) as nontoxic and safe substances: a review. Phytother Res. 2018;32:985–95. doi:10.1002/ptr.6054
  24. [24]24. Chainani Wu N, Silverman S, Reingold A, et al. A randomized, placebo controlled, double blind clinical trial of curcuminoids in oral lichen planus. Phytomedicine. 2007;14(5):437–46. doi:10.1016/j.phymed.2007.05.006
  25. [25]25. Pivari F, Mingione A, Brasacchio C, Soldati L. Curcumin and type 2 diabetes mellitus: prevention and treatment. Nutrients. 2019;11(8):1837. doi:10.3390/nu11081837
  26. [26]26. Jiménez Osorio AS, Castro Quintero D, Tapia E, et al. Curcumin supplementation in diabetic and non diabetic chronic kidney disease: effects on lipoperoxidation and renal function. Clin Nutr ESPEN. 2020;36:127–33. doi:10.1016/j.clnesp.2019.12.014
  27. [27]27. Jurgenka JW, et al. Nanocurcumin and rheumatoid arthritis: immunologic outcomes from double blind randomized controlled trial. Int J Rheum Dis. 2019;22(10):1857–62. doi:10.1111/1756 185X.13688
  28. [28]28. Gu Y, Niu Q, Zhang Q, Zhao Y. Ameliorative effects of curcumin on type 2 diabetes mellitus. Molecules. 2024;29(12):2934. doi:10.3390/molecules29122934
  29. [29]29. Alsulaim AK, Almutaz TH, Albati AA, Rahmani AH. Therapeutic potential of curcumin in prevention of streptozocin induced diabetes by modulation of oxidative stress and inflammation. Molecules. 2023;29(1):128. doi:10.3390/molecules29010128
  30. [30]30. Pathomwichaiwat T, et al. Effects of turmeric supplementation on glucose metabolism in diabetes and metabolic syndrome: an umbrella review. PLoS One. 2023;18(7):e0288997. doi:10.1371/journal.pone.0288997

Authors (5)

Prabha Sahu

Shri Rawatpura Sarkar Institut...

View all publications →

Laxmi Sen

Shri Balaji Institute of Pharm...

View all publications →

Aditya Surana

College & address - Royal Coll...

View all publications →

Renuka Soni

Faculty of Pharmaceutical Scie...

View all publications →

Harsh Kumar Tamrakar

Kamla Institute of Pharmaceuti...

View all publications →

Download Article

PDF

Best for printing and citation

File size: 1.5 MB
Format: PDF

Download Article

PDF

Best for printing and citation

File size: 1.5 MB
Format: PDF

Article Information

Published in:

IJPHDT, Vol-3, Issue-04, April-2026 (Vol. 3, Issue 4, 2026)

IJPHDT430009

IJPHDT-01-000240

81-95

2026-04-24

Article Impact

Views:2,665
Downloads:1,233
scite_
PlumX Metrics Badge

How to Cite

Sahu & Sen & Surana & Soni & Kumar, H. (2026). Multitargeted Mechanisms of Curcuma longa in Chronic Disease: Bridging Ethnopharmacology and Evidence-Based Metabolic and Inflammatory Therapy. International Journal of Pharmacognosy and Herbal Drug Technology, 3(4), 81-95. DOI:https://doi.org/10.64063/3049-1630.vol3.issue4.000240

Article Actions

Whatsapp